arrow
J

Jeanette E. Eckel-Passow

Mayo Clinic
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma

与 RAF/MEK 抑制剂阿伏美替尼和 FAK 抑制剂德法替尼联合治疗脑膜瘤的预临床模型

2026-08-120
OA
MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma

MRI深度学习用于区分胶质母细胞瘤(IDH野生型)与中枢神经系统弥漫性大B细胞淋巴瘤

2026-05-010
PRE
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

MDM2抑制剂brigimadlin在胶质母细胞瘤患者源性异种移植模型中的药代动力学-药效学-疗效建模

2026-01-010
OA
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH-wildtype

IDH野生型星形细胞瘤的病理学诊断与分子分型在临床、影像学及基因组学改变方面的比较

2026-01-010
OA
Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation

胶质母细胞瘤中缺乏坏死和微血管增生的多变量生存风险分层

2025-11-010
OAAI
Differentiation of IDH-Wildtype Glioblastoma and Primary Central Nervous System Lymphoma Using 3D Deep Learning on MRI

利用3D深度学习在MRI上区分IDH-Wildtype胶质母细胞瘤和原发性中枢神经系统淋巴瘤

2025-11-010
OAAI
LONGITUDINAL CEREBROSPINAL FLUID D-2-HYDROXYGLUTARATE FOR DISEASE MONITORING IN PATIENTS WITH IDH-MUTANT GLIOMAS

纵向脑脊液D-2-羟基戊二酸盐在IDH突变型胶质瘤患者疾病监测中的应用

2025-11-010
PRE
DIFFERENTIATING ADULT DIFFUSE IDH-MUTANT GLIOMA FROM MOLECULAR GLIOBLASTOMA IDH-WILDTYPE USING DEEP LEARNING ON MRI

利用深度学习在MRI上区分成人弥漫性IDH突变型胶质瘤与分子胶质母细胞瘤IDH野生型

2025-11-010
OAAI
DNA copy number clustering reveals alterations that influence survival in primary IDH-mutant astrocytoma patients

DNA拷贝数聚类分析揭示了影响IDH突变型星形细胞瘤患者生存的基因改变。

2025-11-010
OAAI
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts
2025-06-011
PRE
Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants

解析胶质瘤发生的生物学机制:评估IDH肿瘤突变与生殖细胞变异的相互作用

2025-01-010
OAAI
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
2024-11-190
OAAI
CURRENT NEURO-ONCOLOGY CAPACITY IN SUB-SAHARAN AFRICAN COUNTRIES: A QUESTIONNAIRE-BASED SURVEY
2024-11-110
PRE